Alan Wake 2 Surpasses 3 Million Sales as Remedy Prepares for Control Resonant Launch

Remedy Entertainment has announced that Alan Wake 2 has exceeded 3 million copies sold, a milestone reached during the second quarter of 2024 according to the studio's half-year financial report. The investigative horror shooter, developed and published by Remedy, launched across PC, PS5, and Xbox Series X/S to critical acclaim but a muted commercial reception that saw it move only 1 million units at launch. For a studio that has historically operated on longer sales tails rather than blockbuster openings, this latest figure represents a meaningful acceleration — the game passed 2 million copies in February 2023 and only began turning a profit around that same time, nearly recouping its development and marketing budget a year prior.

The news arrives alongside a broader financial picture that shows declines across revenue, profit, and cashflow for the January-to-June period. Remedy attributes this to expected spending on the development and marketing of Control Resonant, the studio's next major release, alongside continued investment in the Max Payne 1 & 2 remakes and a third unannounced project currently in production readiness. While Alan Wake 2's long-term trajectory validates Remedy's patience, the studio's new CEO — who took the role in February — has been blunt about the bigger picture:

"he believes both Alan Wake and Control 'should have sold more,' and that the studio 'hasn't achieved half of the potential for the products that we make.'"

Remedy's new CEO

Alan Wake 2's Wild $70 Success

Alan Wake 2's path to 3 million copies has been notably gradual compared to typical AAA benchmarks. The game sold 1 million copies at launch — a respectable figure that nonetheless fell short of recouping its Epic Games-funded budget immediately. It took roughly a year to approach break-even, and another year to add the next million sales after the 2 million announcement in February 2023. This slow burn reflects both the game's niche investigative horror shooter positioning and its PC exclusivity to the Epic Games Store, a decision many observers argue has limited its reach. Steam remains the dominant PC marketplace, and absence from it almost certainly left revenue on the table, even if Epic's funding helped de-risk development.

That said, the 3 million figure makes Alan Wake 2 Remedy's fastest-selling game to date, a distinction that matters for a studio building a connected universe. The original Control saw its own sales spike in Q2 2024, beating the previous year's record for the same quarter — likely driven by anticipation for Control Resonant. This halo effect suggests Remedy's strategy of interlinked storytelling is creating a compounding audience, even if individual launches don't explode out of the gate. For players, the milestone means continued support for a game that has already received substantial post-launch content, and confidence that the Remedy Connected Universe isn't being abandoned despite the studio's current spending crunch.

3M Sales Later: Remedy's Next Big Gamble

Remedy's immediate focus is Control Resonant, a stylised action game slated for 24 September on PC, PS5, and Xbox Series X/S. The financial report makes clear that marketing and development spend for this title is the primary driver behind the current downturn in revenue and cashflow — a calculated bet that the Control sequel will deliver a stronger commercial launch than its predecessor. Beyond that, the Max Payne 1 & 2 remakes remain in full production, while a third unannounced project sits in "production readiness," a stage that typically precedes full development greenlight. This three-project pipeline represents Remedy's most ambitious slate ever, but it also concentrates risk: the studio needs at least one of these to hit significantly harder than Alan Wake 2 did at launch to justify the expanded cost base.

The CEO's candid assessment — that Remedy has achieved less than half its potential — frames the current moment as a pivot point. Alan Wake 2's eventual profitability proves the studio's creative direction resonates, but the commercial ceiling remains frustratingly low for the investment required. Control Resonant's September launch will be the first real test of whether Remedy can translate critical acclaim into the kind of launch momentum that changes the financial trajectory. For now, 3 million copies is a milestone worth marking — just not one the studio intends to settle for.